Proanthocyanidin protects against cisplatin-induced nephrotoxicity

Area of Science:

• Biochemistry
• Toxicology
• Pharmacology

Background:

• Cisplatin (CP) is a vital chemotherapy drug with known nephrotoxicity.
• This kidney damage is linked to increased reactive oxygen species (ROS) production.
• Proanthocyanidin (PA) is investigated for its potential protective effects.

Purpose of the Study:

• To evaluate the therapeutic efficacy of proanthocyanidin (PA) against cisplatin-induced (CP) nephrotoxicity in a mouse model.
• To assess the impact of PA on biochemical and oxidative stress markers in CP-treated mice.

Main Methods:

• Mice were treated with cisplatin (CP) to induce nephrotoxicity.
• Proanthocyanidin (PA) was administered at varying doses to assess its protective effects.
• Kidney function markers (urea, creatinine), inflammatory cytokine (IL-6), lipid peroxidation (malondialdehyde - MDA), and antioxidant levels (glutathione - GSH, superoxide dismutase - SOD activity) were measured.

Main Results:

• CP treatment significantly increased urea, creatinine, and IL-6 levels in mouse kidneys.
• CP administration led to higher MDA and lower GSH levels, along with decreased SOD activity.
• Proanthocyanidin (PA) administration dose-dependently reversed these CP-induced alterations, mitigating oxidative stress and improving kidney function markers.

Conclusions:

• Proanthocyanidin (PA) demonstrates significant therapeutic efficacy in attenuating cisplatin-induced (CP) nephrotoxicity.
• PA exhibits antioxidant properties that counteract CP-induced oxidative stress in the kidneys.
• These findings suggest PA as a potential adjuvant therapy to mitigate CP-related kidney damage.